CORMEDIX INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
CORMEDIX INC. (CRMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-03-05
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 0.00%.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2020-03-31 was 0.00%.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-06-30 | 0.00% 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-05 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-10-30 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | 0.00% 10-K · filed 2025-03-25 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | 0.00% 10-K · filed 2024-03-12 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 0.00% 10-K · filed 2023-03-30 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2021-08-12 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-29 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | 0.00% 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-30 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2019-11-14 | |||
| 2019-06-30 | 0.00% 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | 0.00% 10-Q · filed 2019-05-13 | |||
| 2018-12-31 | 0.00% 10-K · filed 2020-03-16 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2018-11-14 | 0.00% 10-Q · filed 2018-11-14 | ||
| 2018-06-30 | 0.00% 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-13 | |||
| 2017-09-30 | 0.00% 10-Q · filed 2018-11-14 | 0.00% 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | 0.00% 10-Q · filed 2018-08-14 | |||
| 2017-03-31 | 0.00% 10-Q · filed 2018-05-15 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2017-11-09 | |||
| 2016-06-30 | 0.00% 10-Q · filed 2017-08-09 | |||
| 2016-03-31 | 0.00% 10-Q · filed 2017-05-10 | |||
| 2014-03-31 | 0.00% 10-Q · filed 2014-05-15 | |||
| 2013-12-31 | 0.00% 10-K · filed 2014-03-31 | |||
| 2013-09-30 | 0.00% 10-Q/A · filed 2014-03-04 | |||
| 2013-06-30 | 0.00% 10-Q/A · filed 2014-03-04 | |||
| 2013-03-31 | 0.00% 10-Q · filed 2014-05-15 | |||
| 2012-12-31 | 0.00% 10-K · filed 2014-03-31 | |||
| 2012-09-30 | 0.00% 10-Q/A · filed 2014-03-04 | |||
| 2012-06-30 | 0.00% 10-Q/A · filed 2014-03-04 | |||
| 2012-03-31 | 0.00% 10-Q/A · filed 2014-03-04 | |||
| 2011-12-31 | 0.00% 10-K/A · filed 2014-03-04 | |||
| 2011-09-30 | 0.00% 10-Q/A · filed 2013-03-27 | |||
| 2011-06-30 | 0.00% 10-Q/A · filed 2012-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |